OSCIENT PHARMACEUTICALS CORP Form 8-K May 03, 2004

## **SECURITIES**

SECURITII	ES AND EXCHANGE CO	OMMISSION
	Washington, D.C. 20549	
	FORM 8-K	
	CURRENT REPORT	
	Pursuant to Section 13 or 15(d) of	
ТН	E SECURITIES EXCHANGE ACT O	F 1934
Date o	of Report (Date of Earliest Event Reported): Ma	ay 3, 2004
OSCIENT PHA	RMACEUTICALS (Exact name of registrant as specified in its charte	
		,
Massachusetts (State or other jurisdiction	0-10824 (Commission	04-2297484 (I.R.S. Employer
of incorporation)	File Number)	Identification Number)

100 Beaver Street

Waltham, Massachusetts 02453

(Address of principal executive offices, including zip code)

(781) 398-2300

(Registrant s telephone number, including area code)

Item 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
99.1 Press Release issued by Oscient Pharmaceuticals Corporation on May 3, 2004.
Item 9. REGULATION FD DISCLOSURE
On May 3, 2004, Oscient Pharmaceuticals Corporation issued a press release announcing its intention to issue convertible notes. A copy of the press release is attached hereto as Exhibit 99.1.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### OSCIENT PHARMACEUTICALS CORPORATION

By: /s/ Steven M. Rauscher

Name: Steven M. Rauscher

Title: President and Chief Executive Officer

Date: May 3, 2004

### EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release issued by Oscient Pharmaceuticals Corporation on May 3, 2004.

4